RAS–MAPK pathway-driven tumor progression is associated with loss of CIC and other genomic aberrations in neuroblastoma
TF Eleveld, L Schild, J Koster, DA Zwijnenburg… - Cancer research, 2018 - AACR
TF Eleveld, L Schild, J Koster, DA Zwijnenburg, LK Alles, ME Ebus, R Volckmann, GA Tijtgat…
Cancer research, 2018•AACRMutations affecting the RAS–MAPK pathway frequently occur in relapsed neuroblastoma
tumors, which suggests that activation of this pathway is associated with a more aggressive
phenotype. To explore this hypothesis, we generated several model systems to define a
neuroblastoma RAS–MAPK pathway signature. Activation of this pathway in primary tumors
indeed correlated with poor survival and was associated with known activating mutations in
ALK and other RAS–MAPK pathway genes. Integrative analysis showed that mutations in …
tumors, which suggests that activation of this pathway is associated with a more aggressive
phenotype. To explore this hypothesis, we generated several model systems to define a
neuroblastoma RAS–MAPK pathway signature. Activation of this pathway in primary tumors
indeed correlated with poor survival and was associated with known activating mutations in
ALK and other RAS–MAPK pathway genes. Integrative analysis showed that mutations in …
Abstract
Mutations affecting the RAS–MAPK pathway frequently occur in relapsed neuroblastoma tumors, which suggests that activation of this pathway is associated with a more aggressive phenotype. To explore this hypothesis, we generated several model systems to define a neuroblastoma RAS–MAPK pathway signature. Activation of this pathway in primary tumors indeed correlated with poor survival and was associated with known activating mutations in ALK and other RAS–MAPK pathway genes. Integrative analysis showed that mutations in PHOX2B, CIC, and DMD were also associated with an activated RAS–MAPK pathway. Mutation of PHOX2B and deletion of CIC in neuroblastoma cell lines induced activation of the RAS–MAPK pathway. This activation was independent of phosphorylated ERK in CIC knockout systems. Furthermore, deletion of CIC caused a significant increase in tumor growth in vivo. These results show that the RAS–MAPK pathway is involved in tumor progression and establish CIC as a powerful tumor suppressor that functions downstream of this pathway in neuroblastoma.
Significance: This work identifies CIC as a powerful tumor suppressor affecting the RAS-MAPK pathway in neuroblastoma and reinforces the importance of mutation-driven activation of this pathway in cancer. Cancer Res; 78(21); 6297–307. ©2018 AACR.
AACR